{"id":"ct-p6","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tuberculosis reactivation risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CT-P6 is a biosimilar of infliximab, a chimeric monoclonal antibody that targets TNF-α, a key pro-inflammatory cytokine. By neutralizing TNF-α, it suppresses the inflammatory cascade involved in autoimmune conditions. This mechanism allows reduction of systemic inflammation and immune-mediated tissue damage in diseases like rheumatoid arthritis and inflammatory bowel disease.","oneSentence":"CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:00.099Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT06136897","phase":"PHASE2","title":"Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-23","conditions":"Malignant Solid Neoplasm","enrollment":35},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03179904","phase":"PHASE2","title":"TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-08-03","conditions":"Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8","enrollment":17},{"nctId":"NCT01196390","phase":"PHASE3","title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-14","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7","enrollment":203},{"nctId":"NCT07407920","phase":"PHASE2","title":"Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-10-09","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma","enrollment":120},{"nctId":"NCT05408845","phase":"PHASE2","title":"Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-03-03","conditions":"Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8","enrollment":146},{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT04108858","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":2},{"nctId":"NCT00770809","phase":"PHASE3","title":"Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-02-24","conditions":"Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7","enrollment":305},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT01275677","phase":"PHASE3","title":"Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-08","conditions":"HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma","enrollment":3270},{"nctId":"NCT06687928","phase":"PHASE1","title":"To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celltrion","startDate":"2025-03-25","conditions":"Healthy","enrollment":200},{"nctId":"NCT00769379","phase":"PHASE3","title":"Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-10","conditions":"Breast Ductal Carcinoma In Situ","enrollment":2014},{"nctId":"NCT06907082","phase":"NA","title":"Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2020-12-28","conditions":"Breast Cancer","enrollment":106},{"nctId":"NCT01084876","phase":"PHASE3","title":"Demonstrate Efficacy and Safety of Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Celltrion","startDate":"2010-06","conditions":"Metastatic Breast Cancer","enrollment":475},{"nctId":"NCT01084863","phase":"PHASE1, PHASE2","title":"Evaluate Safety, Efficacy and Pharmacokinetics","status":"COMPLETED","sponsor":"Celltrion","startDate":"2010-02","conditions":"Metastatic Breast Cancer","enrollment":143},{"nctId":"NCT02162667","phase":"PHASE3","title":"Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Celltrion","startDate":"2014-06","conditions":"HER2-positive Carcinoma of Breast","enrollment":562},{"nctId":"NCT02665637","phase":"PHASE1","title":"Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin","status":"COMPLETED","sponsor":"Celltrion","startDate":"2015-12","conditions":"Healthy Volunteers","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CT-P6","genericName":"CT-P6","companyName":"Celltrion","companyId":"celltrion","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CT-P6 is a monoclonal antibody that binds to and inhibits tumor necrosis factor alpha (TNF-α), reducing inflammatory signaling in autoimmune and inflammatory diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}